John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
Silverman TB, Kuperman GJ, Vanegas A, Sin M, Dimond J, Crew KD, Kukafka R. An applied framework in support of shared decision making about BRCA genetic testing. AMIA Annu Symp Proc. 2018 Dec 5;2018:961-9.
Sin M, McGuinness JE, Trivedi MS, Vanegas A, Silverman TB, Crew KD, Kukafka R. Automatic genetic risk assessment calculation using breast cancer family history data from the EHR compared to self-report. AMIA Annu Symp Proc. 2018 Dec 5;2018:970-8.
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
Mosquin PL, Rothman KJ. Reanalysis of reported associations of beryllium and lung cancer in a large occupational cohort. J Occup Environ Med. 2017 Mar;59(3):274-81. doi: 10.1097/JOM.0000000000000947
Coe AM, Ueng W, Vargas JM, David R, Vanegas A, Infante K, Trivedi M, Yi H, Dimond J, Crew KD, Kukafka R. Usability testing of a web-based decision aid for breast cancer risk assessment among multi-ethnic women. AMIA Annu Symp Proc. 2017 Feb 10;2016:411-20.
Edwards T, Cadigan RJ, Evans JP, Henderson GE. Biobanks containing clinical specimens: defining characteristics, policies, and practices. Clin Biochem. 2014 Mar;47(4-5):245-51. doi: 10.1016/j.clinbiochem.2013.11.023
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Greene BL, Miller JD, Brown TM, Harshman RS, Richerson GT, Doyle JJ. Economic impact of the BP DownShift Program on blood pressure control among commercial driver license employees. J Occup Environ Med. 2009 May 1;51(5):542-53.
Harshman RS, Richerson GT, Hadker N, Greene BL, Brown TM, Foster TS. Impact of a hypertension management/health promotion program on commercial driver's license employees of a self-insured utility company. J Occup Environ Med. 2008 Mar 1;50(3):359-65.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.
Dreyer NA, Loughlin JE, Lanes SF, Rothman KJ. Mortality among employees of a nuclear power company. J Occup Environ Med. 1988 Jan 1;30(12):988-9.